TLSA — Tiziana Life Sciences Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723069 ·
Last close
$1.03
Market Cap
$131.08M
52W High
$1.85
52W Low
$0.87
ADV30
233,312
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 11,495,000 | 4,010,000 | 11,443,000 |
| Dec 2024 | — | — | — | — | 11,284,000 | 3,724,000 | 7,348,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-144,831,000
Inventory
—
Receivables
$3,692,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,132,000 | -18,431,000 | 11,495,000 | 11,443,000 | — | -12,847,000 |
| Dec 2024 | 0 | -15,794,000 | -11,863,000 | 11,284,000 | 7,348,000 | — | -1,526,000 |
| Dec 2023 | 0 | -17,984,000 | -17,691,000 | 12,184,000 | 6,648,000 | — | -15,698,000 |
| Dec 2022 | 0 | -14,586,000 | -15,397,000 | 26,477,000 | 6,906,000 | — | -19,615,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GNLX | GENELUX Corp | $131.83M | $2.94 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $132.23M | $0.94 | — |
| ADCT | ADC Therapeutics SA | $133.55M | $1.05 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $134.82M | $3.15 | — |
| VTVT | vTv Therapeutics Inc. | $127.42M | $32.35 | — |
News headlines (Yahoo Finance, 1h cache)
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
2026-07-31 12:55 · Yahoo
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
2026-07-31 11:00 · Yahoo
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
2026-07-22 11:00 · Yahoo
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
2026-06-25 13:05 · Yahoo
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
2026-06-25 11:00 · Yahoo
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
2026-05-29 22:55 · Yahoo
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
2026-05-28 11:00 · Yahoo
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
2026-05-22 20:48 · Yahoo
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
2026-05-21 15:44 · Yahoo
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
2026-05-21 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.